Is Canopy Growth Stock Finally Worth Buying After Losing 99% of Its Value?

Canopy Growth’s fiscal 2026 revenue rose 6% to $200.4M and cannabis revenue increased 15%, with cash improving to ~$256.5M and net cash of $92M. However, the company remains unprofitable, free cash flow is still negative, and dilution/capital raises remain a risk if profitability lags. The article frames the turnaround as encouraging but not conclusive, keeping a cautious stance despite improving balance-sheet metrics.

Analysis

The key market implication is that Canopy has de-risked survival, not proven equity compounding. In a structurally oversupplied category, a cleaner balance sheet mainly lowers bankruptcy probability and buying time; it does not fix the core problem that operating leverage is still negative and any improvement can be absorbed by price competition or dilution. Near term, that usually means the stock can rally on headline optimism, but the move tends to fade once investors refocus on cash burn and whether earnings quality is actually improving.

The second-order effect is more interesting for competitors: a healthier Canopy can keep spending longer, which is bearish for pricing discipline in Canadian rec and for smaller peers that lack access to capital. That extends the industry’s "survivor's phase" and delays a rationalization that would otherwise improve margins across the group. The real upside catalyst is not incremental cost cutting; it is either a regulatory step-change or a credible path to sustained positive free cash flow, and both are months-to-years away.

Contrarian view: the consensus may be underestimating how much of the equity is already an option on reform, while overestimating the value created by balance-sheet repair. If management misses the 2027 profitability bridge or needs another raise, the current progress becomes mostly a financing story, not an intrinsic value story. The thesis is falsified if operating cash burn narrows faster than expected for two consecutive quarters or if management converts the 2027 EBITDA target into positive free cash flow guidance; absent that, rallies should be treated as sellable.

Key Decisions for Investors

• Do not initiate a strategic long in CGC yet; wait for at least two consecutive quarters of positive operating cash flow inflection or a hard free-cash-flow bridge before paying for the turnaround.
• Tactically fade strength in CGC: sell rallies or use 6-12 month put spreads after any sentiment-driven squeeze, with the view that dilution risk and lack of FCF will cap multiple expansion.
• For relative value, prefer stronger balance-sheet cannabis operators over CGC on any sector rerating; if forced into the group, pair long SNDL versus short CGC to express 'execution + financing discipline' over 'optionality only.'
• Set an alert on equity issuance or guidance changes: any renewed dilution, missed EBITDA milestones, or cash burn re-acceleration is a signal to press the short thesis.